NSW Increases Penalties and Enforcement for Illegal Vape Supply

Nov.19.2024
NSW Increases Penalties and Enforcement for Illegal Vape Supply
The New South Wales Government in Australia has introduced tougher penalties and enforcement measures for illegal vape supply, increasing fines to A$1.54 million and prison terms to seven years.

On November 19, the New South Wales (NSW) Government announced plans to raise the maximum fine for illegal vape supply from A$1,650 to approximately A$1.54 million, with prison sentences increasing from six months to seven years.

 

The NSW Government has introduced the legislation in Parliament, aiming to align state enforcement powers with those of federal agencies. Possession of a commercial quantity of vaping products or retailer possession of vapes will also be classified as illegal.

 

Similar to the Commonwealth vaping reforms, these measures target suppliers of vape products rather than individual users. Over the past year, more than 300,000 vape products have been seized by the government.

 

Between July 1 and September 30, 2024, a total of 362 inspections were conducted, resulting in the seizure of 42,000 products. In comparison, 153,000 products were confiscated from 290 inspections last year. The recent decrease in seizures during the last quarter may reflect market supply disruptions following the implementation of new Commonwealth vaping laws.

 

In October, the NSW Government announced plans to recruit 14 additional enforcement officers to enhance compliance efforts for vaping and tobacco products statewide. 

 

Additionally, they also launched the eCigarette Compliance Program, initially aimed at supporting pharmacists. A dedicated team of compliance officers will visit pharmacies across the state to provide on-site education and guidance.

 

"The prevalence of illegal vaping devices in our community, and in particular among our young people, is deeply concerning. We have a once-in-a-generation opportunity to the stem the tide of this public health challenge," said Ryan Park, the state Minister for Health, 

 

"I am very encouraged by the progress we are making in terms of removing these harmful devices from our streets. And I am pleased to announce that we are augmenting our efforts by introducing harsher penalties to target suppliers."

 

 

Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
British e-liquid manufacturer Riot Labs has introduced a fictional “candidate” called Riot Man around the Clacton parliamentary by-election, seeking to mobilize consumers and retailers against parts of the UK government’s proposed restrictions on vape packaging, device appearance and retail displays. Riot Man is not listed as an official candidate.
Aug.12
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19